FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 353:113-116 July 14, 2005 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Interview Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

How can a drug that is associated with higher rates of both renal dysfunction and death than placebo — and that costs 50 times as much as standard therapies and for which there are no meaningful data on relevant clinical end points — be given to more than 600,000 patients and be promoted throughout the United States for serial outpatient use, an indication not listed on the label?^1,2,3,4,5 The answer to this question can be discerned, at least in part, from a review of the clinical development and marketing of nesiritide: recombinant human brain natriuretic peptide.

On May, 17, 2005, . . . [Full Text of this Article]

Source Information

Dr. Topol is provost of Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and chair of the Department of Cardiovascular Medicine at the Cleveland Clinic, Cleveland.

An interview with Dr. Topol can be heard at www.nejm.org.

Related Letters:

Nesiritide — Not Verified
Sackner-Bernstein J., Aaronson K. D., Schreiner G., April P. A., Topol E. J.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:1525-1527, Oct 6, 2005. Correspondence

This article has been cited by other articles:

• Alsaddique, A. A., Royse, A. G., Royse, C. F., Fouda, M. A. (2009). Management of diastolic heart failure following cardiac surgery. Eur. J. Cardiothorac. Surg. 35: 241-249 [Abstract] [Full Text]  
• Schwarz, L. R. (2008). Industry promotion of unlabeled uses. Am J Health Syst Pharm 65: 908-910 [Full Text]  
• Kesselheim, A. S., Avorn, J. (2008). Pharmaceutical Promotion to Physicians and First Amendment Rights. NEJM 358: 1727-1732 [Full Text]  
• De Luca, L., Mebazaa, A., Filippatos, G., Parissis, J. T., Bohm, M., Voors, A. A., Nieminen, M., Zannad, F., Rhodes, A., El-Banayosy, A., Dickstein, K., Gheorghiade, M. (2008). Overview of emerging pharmacologic agents for acute heart failure syndromes. Eur J Heart Fail 10: 201-213 [Abstract] [Full Text]  
• Steinberg, D. I., Mayer, A. (2007). Lipoprotein-Associated Phospholipase A2 and Risk Stratification for Cardiovascular Disease: Not Ready for 'Prime Time'. Mayo Clin Proc. 82: 155-157 [Full Text]  
• deGoma, E. M., Vagelos, R. H., Fowler, M. B., Ashley, E. A. (2006). Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside. J Am Coll Cardiol 48: 2397-2409 [Abstract] [Full Text]  
• Hauptman, P. J., Schnitzler, M. A., Swindle, J., Burroughs, T. E. (2006). Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure.. JAMA 296: 1877-1884 [Abstract] [Full Text]  
• London, B. (2006). Natriuretic Peptides and Cardiac Hypertrophy. J Am Coll Cardiol 48: 506-507 [Full Text]  
• Kesselheim, A. S., Fischer, M. A., Avorn, J. (2006). The rise and fall of Natrecor for congestive heart failure: implications for drug policy.. Health Aff (Millwood) 25: 1095-1102 [Abstract] [Full Text]  
• Brown, S. D., Daly, J. C., Kalish, L. A., McDaniel, S. A. (2006). Financial Disclosures of Scientific Papers Presented at the 2003 RSNA Annual Meeting: Association with Reporting of Non-Food and Drug Administration-approved Uses of Industry Products. Radiology 239: 849-855 [Abstract] [Full Text]  
• Tindall, E. A., Fox, D. A. (2006). Treatment for rheumatic disorders.. NEJM 354: 1322-1323 [Full Text]  
• Nishikimi, T., Maeda, N., Matsuoka, H. (2006). The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69: 318-328 [Abstract] [Full Text]  
• Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Schumock, G. T., Grim, P., Hunkler, R. J., Hontz, K. M. (2006). Projecting future drug expenditures--2006. Am J Health Syst Pharm 63: 123-138 [Abstract] [Full Text]  
• Dzik, W. H. (2006). Off-label Reports of New Biologics: Exciting New Therapy or Dubious Research? Examples From Recombinant Activated Factor VII. J Intensive Care Med 21: 54-59  
• Clerico, A., Recchia, F. A., Passino, C., Emdin, M. (2006). Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am. J. Physiol. Heart Circ. Physiol. 290: H17-H29 [Abstract] [Full Text]  
• Sackner-Bernstein, J., Aaronson, K. D., Schreiner, G., April, P. A., Topol, E. J. (2005). Nesiritide--not verified.. NEJM 353: 1525-1527 [Full Text]  
• (2005). Controversies in cardiology. Circulation 112: iv-iv [Full Text]